US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair (NECC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04852783|
Recruitment Status : Recruiting
First Posted : April 21, 2021
Last Update Posted : November 9, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Aneurysm, Intracranial||Device: Contour Neurovascular System||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||220 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This trial is a prospective, multicenter single-arm study.|
|Masking:||None (Open Label)|
|Official Title:||US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair|
|Actual Study Start Date :||August 6, 2021|
|Estimated Primary Completion Date :||September 2023|
|Estimated Study Completion Date :||September 2027|
- Device: Contour Neurovascular System
Endovascular embolization of wide-necked, bifurcated saccular intracranial aneurysms.
- Primary Safety Endpoint: Death or stroke within 30 days of treatment or ipsilateral stroke or neurological death between 30 days and 1 year. [ Time Frame: 30 days ]Death or stroke within 30 days of treatment or ipsilateral stroke or neurological death between 30 days and 1 year.
- Primary Effectiveness Endpoint: Complete occlusion of the aneurysm with Contour without retreatment, recurrent subarachnoid hemorrhage, or significant parent artery stenosis at one (1) year after treatment as assessed by the angiographic core laboratory. [ Time Frame: 1 year ]Complete occlusion of the aneurysm with Contour as defined by complete aneurysm occlusion (Raymond Roy Scale , of 1) without retreatment, recurrent subarachnoid hemorrhage, or significant parent artery stenosis (> 50% stenosis) at one (1) year after treatment as assessed by the angiographic core laboratory.
- Key Secondary Effectiveness Endpoint: The trial's secondary endpoint is the proportion of subjects with angiographic aneurysmal recurrence defined as aneurysm growth or recanalization at one (1) year after treatment. [ Time Frame: 1 year ]The trial's secondary endpoint is the proportion of subjects with angiographic aneurysmal recurrence defined as aneurysm growth or recanalization at one (1) year after treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 75 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient is 18-75 years of age at the time of screening.
- Patient has a single ruptured or unruptured IA requiring treatment. If the patient has an additional IA requiring treatment, the additional IA must not require treatment within 60 days of the index procedure.
The target IA must have the following characteristics:
- Saccular morphology
- Located at a bifurcation in the anterior or posterior circulation
- Aneurysm neck diameter between 2 and 10 mm and aneurysm equatorial diameter between 2 and 10.5 mm
- Wide-necked, defined as neck size ≥ 4 mm or a dome/neck ratio < 2
- Patient may be treated with Contour without the use of additional implanted devices.
- Patient is able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule.
Patient or legally authorized representative has signed and dated an institutional review board (IRB)/Ethics Committee (EC)-approved written informed consent prior to initiation of any study procedures.
FOR PATIENTS WITH UNRUPTURED ANEURYSM
- Patient meets the criteria outlined in the "Guidelines for the Management of Patients With Unruptured Intracranial Aneurysms" as published by the AHA/ASA FOR PATIENTS WITH RUPTURED ANEURYSM
- Patient meets the criteria outlined in the "Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association" as published by the AHA/ASA.
- Patient must be neurologically stable with Hunt & Hess Score of I, II or III.
- Anatomy or physiology considered unsuitable for endovascular treatment with the Contour device by the implanting physician and/or the Patient Selection Committee
- Target IA contains other devices/implants (e.g., coils) that could interfere with the correct placement of the Contour device
- Subject has a known, untreatable hypersensitivity to contrast dye, iodine, or any component of the treatment device.
- Contraindication to anticoagulants or anti-platelet medications
- Stenosis of the target IA's parent vessel is >50%
- Anticoagulation medications (e.g., warfarin) that cannot be discontinued
- Acute / chronic renal failure (unless on dialysis) and/or creatinine > 2.00 mg/dl or > 182 μmol/L
- Vascular disease or other vascular anomaly that precluded the necessary access to the aneurysm for use of the study device.
- Clinical, angiographic or CT evidence of vasospasm, vasculitis, an intracranial tumor (except small meningioma) or any other intracranial vascular malformations on presentation.
- Conditions placing them at high risk for ischemic stroke or had exhibited ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within the prior 60-days.
- Any circulatory, neurovascular, cardiovascular, or neurologic conditions that can result in unstable neurological symptoms (e.g., multiple sclerosis, established seizure disorder).
- modified Rankin Scale (mRS) score ≥ 2 prior to presentation or rupture (as applicable).
- SAH from a non-index aneurysm or any other intracranial hemorrhage within 90 days.
- Physical, neurologic or psychiatric conditions which precluded his/her ability to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule.
- Pregnant, breastfeeding or planning pregnancy in the next 2 years
- Subject is enrolled in another device or drug study in which participation could confound study results.
- Life expectancy of less than 2 years due to an illness or condition other than the index intracranial aneurysm.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04852783
|Contact: Lori E Adels, PhD||510-651-4000 ext email@example.com|
|Principal Investigator:||Pascal M Jabbour, MD||Jefferson University Hospitals|
|Principal Investigator:||Demetrius Lopes, MD||Advocate Medical Group - Brain and Spine Institute|
|Responsible Party:||Cerus Endovascular, Ltd|
|Other Study ID Numbers:||
|First Posted:||April 21, 2021 Key Record Dates|
|Last Update Posted:||November 9, 2022|
|Last Verified:||November 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Device Product Not Approved or Cleared by U.S. FDA:||Yes|
Intracranial Arterial Diseases
Central Nervous System Diseases
Nervous System Diseases